Non-Small Cell Lung Cancer

Adding nivolumab to neoadjuvant platinum-based chemotherapy can improve survival in patients with stage IIIA-B non-small cell lung cancer, new data suggest.

Sugemalimab consolidation improved progression-free survival, when compared with placebo, in patients with unresectable, stage III non-small cell lung cancer.

Sintilimab, IBI305, and chemotherapy could be a new standard of care for patients with EGFR-mutant NSCLC that progressed on an EGFR TKI.

Guideline-adherent care was associated with better survival, regardless of disease stage.

Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.

The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.

TACTI-002, enrolled 114 patients with untreated locally advanced or metastatic non-small cell lung cancer, unselected for PD-L1 expression.

Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.

The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.